Funding for this research was provided by:
Alexion Pharmaceuticals
Article History
Received: 23 March 2021
Accepted: 31 May 2021
First Online: 2 July 2021
Declarations
:
: The study design was reviewed and approved by the ethics committee of the University of Würzburg, Germany (No. 9/18).
: All participants provided signed informed consent before enrollment.
: All authors have agreed for the final version of this paper to be submitted for publication.
: LS, the clinical study investigator, has received consultancy fees and institutional research funding from Alexion Pharmaceuticals, Inc. DR has no conflicts of interest to disclose. AP is employed by Alexion and may have stock options. FG is a clinical study investigator and has received speaker honoraria from Alexion Pharmaceuticals, Inc.